Re-evaluating the approach to drug target discovery in multidrug-resistant Gram-negative bacilli

Future Microbiology

Volumn 9, Issue 10, 2014, Pages 1113-1116

  Umland, Timothy C ^a,b   Wayne Schultz, L ^a,b   Russo, Thomas A ^b,c,d  

^a HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

Acinetobacter baumannii; Antibiotic target; Bacterial drug target; Essential genes; Gram negative bacilli; Multidrug resistant

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEMASE; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER BAYLYI; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIOSTASIS; CARBON SOURCE; DRUG COST; DRUG DESIGN; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG SCREENING; DRUG TARGETING; EDITORIAL; ESSENTIAL GENE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; PHENOTYPE; POSTANTIBIOTIC EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIAL GENE; DRUG DEVELOPMENT; DRUG EFFECTS; ISOLATION AND PURIFICATION; PROCEDURES; TRENDS;

ACINETOBACTER BAUMANNII; BACILLI (CLASS); BACTERIA (MICROORGANISMS); NEGIBACTERIA;

ANTI-INFECTIVE AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, BACTERIAL; GENES, ESSENTIAL; GRAM-NEGATIVE BACTERIA;

EID: 84911481507     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/FMB.14.72     Document Type: Editorial

References (20)

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
2. Napier BA, Burd EM, Satola SW et al. Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. MBio 4(3), e00021-e00013 (2013).
3. Antibiotic Resistance Threats in the United States, 2013. U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA (2013).
4. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J. Antibiot. 66(10), 571-591 (2013).
5. Kirst HA. Developing new antibacterials through natural product research. Expert Opin. Drug Discov. 8(5), 479-493 (2013).
6. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. Challenges of antibacterial discovery revisited. Ann. NY Acad. Sci. 1213, 5-19 (2010).
7. Macielag MJ. Chemical properties of antimicrobials and their uniqueness. In: Antibiotic Discovery and Development. Dougherty TJ, Pucci MJ (Eds). Springer, New York, NY, USA 793-820 (2012).
8. Luo H, Lin Y, Gao F, Zhang CT, Zhang R. DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res. 42, D574-D580 (2014).
9. Panjkovich A, Gibert I, Daura X. antibacTR: dynamic antibacterial-drug-target ranking integrating comparative genomics, structural analysis and experimental annotation. BMC Genomics 15, 36 (2014).
10. Salama NR, Shepherd B, Falkow S. Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. J. Bacteriol. 186(23), 7926-7935 (2004).
11. D'elia MA, Pereira MP, Brown ED. Are essential genes really essential? Trends Microbiol. 17(10), 433-438 (2009).
12. Joyce AR, Reed JL, White A et al. Experimental and computational assessment of conditionally essential genes in Escherichia coli. J. Bacteriol. 188(23), 8259-8271 (2006).
13. Van Opijnen T, Camilli A. A fine scale phenotype-genotype virulence map of a bacterial pathogen. Genome Res. 22(12), 2541-2551 (2012).
14. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458(7234), 83-86 (2009).
15. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl Acad. Sci. USA 108(37), 15378-15383 (2011).
16. Russo TA, Luke NR, Beanan JM et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect. Immun. 78(9), 3993-4000 (2010).
17. Russo TA, Macdonald U, Beanan JM et al. Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. J. Infect. Dis. 199(4), 513-521 (2009).
18. Umland TC, Schultz LW, MacDonald U, Beanan JM, Olson R, Russo TA. In vivo -validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media. MBio 3(4), pii: e00113-12 (2012).
19. Fahnoe KC, Flanagan ME, Gibson G, Shanmugasundaram V, Che Y, Tomaras AP. Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in Gram-negative pathogens. PLoS ONE 7(12), e51732 (2012).
20. Silver LL. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24(1), 71-109 (2011).